Background: Colorectal cancer screening can decrease morbidity and mortality. However, there are widespread differences in the implementation of programmes and choice of strategy. The primary objective of this study was to estimate lifelong costs and health outcomes of two of the currently most preferred methods of screening for colorectal cancer: colonoscopy and sensitive faecal immunochemical test (FIT).
Introduction
Colorectal cancer is the third most commonly diagnosed cancer in the world 1 , and is associated with mortality and morbidity in the affected individuals with high costs to society. Its natural history and the polyp-cancer pathway have been well known for several decades. Cancer can be prevented to a large extent by removing polyps. In addition, the early-stage detection of colorectal cancer often results in lower mortality rates. Hence, several guidelines, such as those of the US Preventive Services Task Force 2,3 , the Gastroenterology Multi-Society Task Force 4, 5 and the American Cancer Society 6 , have recommended colorectal cancer screening for asymptomatic average-risk individuals 7, 8 .
Several methods with different attributes, such as colonoscopy, faecal occult blood test, faecal immunochemical test (FIT) and sigmoidoscopy, are already in use in screening programmes. However, there is a widespread difference in implementation and strategies followed between countries 9 . All the screening options are considered to have clinical benefits 10 -12 , but have different effects on limited healthcare resources (such as supply of endoscopists) 13 . Two of the most preferred methods are colonoscopy and FIT 9 . Colonoscopy is often seen as the standard, whereas FIT, followed by colonoscopy when FIT is positive, is less sensitive but has higher participation rates and limits the need for colonoscopy. Both methods have been shown previously to be clinically effective and cost-effective compared with no screening 14 -18 . However, the relative effectiveness of these screening methods is yet to be studied head-to-head for different programme designs.
The SCREESCO study (NCT02078804) is an RCT of colorectal cancer screening, which is sponsored by and run in 18 of the 21 Swedish county councils, with a total population of 7⋅5 million. The study is three-armed and has an inclusion period of 3 years, with all participants aged 60 years at the time of enrolment. The target recruitment is 20 000 people invited for a single colonoscopy, 60 000 to do a high-sensitivity (cut-off value 10 μg) FIT in years 1 and 3, and 120 000 as controls. The follow-up time is 15 years.
As the screening methods and clinical panorama surrounding screening programmes change constantly (for instance, with the introduction of new technology to treat colorectal cancer and changing disease incidence), one has to consider a 'moving target' when choosing the most appropriate alternative. The clinical and economic effects of specific screening options and the optimal way to screen a population change over time. It could therefore be unwise to wait for long-term follow-up data from RCTs of screening programmes before making decisions about implementation, as the results of the studies and the technology itself may be outdated when such data become available. Hence, new and updated simulation models are needed as an adjunct to clinical studies to enable decision-makers to make informed predictions about the future.
The primary aim of the present study was to estimate the long-term costs and health outcomes of four strategies for colorectal cancer screening compared with no screening. The analysis was based on recently available data in the scientific literature and early experience from the SCREESCO study. A secondary aim was to calculate the uncertainties in the cost-effectiveness results and single-model inputs, such as the importance of the participation rate, age at initiation of screening and disease progression.
Methods

Model overview
The cost-effectiveness analysis of colorectal cancer screening was based on a Markov decision analysis model. The data used in this study were obtained mainly from the published literature and early experience from the SCREESCO study. In the model, the remaining life of a hypothetical population of Swedish 60-year-olds was simulated with an emphasis on colorectal cancer and its disease progression, polyp-cancer pathway, detection and treatment. The model consists of a number of different health states that the simulated individuals can experience. It deploys fixed-time cycles, and in each cycle the simulated individual has a certain probability of moving to another health state. The probabilities of staying or transitioning into another health state, together with risks of various events, were obtained from the published literature. The model was developed in Microsoft ® Excel (Microsoft, Redmond, Washington, USA), deployed a lifelong time horizon, had a healthcare payer perspective and used 1-year cycles in which transitions could take place. An annual discount rate of 3 per cent for both effects and costs was used as the base case, in accordance with the recommendation from the Swedish authorities 19 . Discounting is the practice of weighting future gains and losses less heavily than those that occur in the present. This is done to account for the fact that, owing to uncertainty, individuals typically prefer benefits now rather than delaying the same benefits until sometime in the future. The starting age of 60 years was chosen in this analysis as this was the age at which individuals were invited to screening in the SCREESCO study. Fig. 1 shows the model structure and most important health states.
Simulation overview
The cornerstone of the model is the simulation of disease progression and the impact of screening. When the simulation starts, all simulated individuals at the age of 60 years are invited to screening, in which they may or may not participate. At that time, all individuals are either in the health state characterized by normal bowel or in a health state with currently undiagnosed adenoma or colorectal cancer: low-risk adenoma, high-risk adenoma, local colorectal cancer, regional colorectal cancer or distant colorectal cancer. According to Swedish clinical guidelines, low-risk adenomas are defined as those no larger than 10 mm, with tubular growth and low-grade dysplasia. High-risk adenomas are defined as having one of the following characteristics: larger than 10 mm, tubovillous or villous growth and high-grade dysplasia. Health states representing colorectal cancer are defined according to the AJCC as stage I-II (local), stage III (regional) and stage IV (distant). Over time, there is a certain annual risk of individuals with a normal bowel developing low-risk adenomas. Low-risk adenomas can develop into high-risk adenomas, which can develop into undiagnosed colorectal cancer (Fig. 1) . These progression rates are not well studied in the scientific literature. Therefore, the authors relied on indirect methods that used real-world prevalence/incidence data and mathematical methods for estimating the yearly progression rates 20 . Also in the model is a certain yearly probability that an unknown condition, such adenoma Any adenomas detected are assumed to be removed with further follow-up, whereas colorectal cancer is treated according to treatment guidelines. Patients with colorectal cancer have a risk of dying from the disease and also from procedure-related events if treated or screened. The annual mortality rates for patients diagnosed with local, regional and distant colorectal cancer for the first 5 years were obtained directly from the Swedish national colorectal cancer registries (data from 2009-2013) 21 . Colorectal cancer-related mortality was dependent on the age of the patient, the stage of cancer, and the time in the current cancer stage. From the fifth year onwards, cancer-specific mortality rates were extrapolated based on mortality in the previous years by using Weibull curves. The procedure-related mortality from colonoscopy was obtained from a meta-analysis of complications from the examinations 22 . Irrespective of the bowel status, all simulated individuals had a risk of death from other causes (non-colorectal). This standard mortality was dependent on the age and sex of the simulated individuals, and was retrieved from the national statistics of the general population in Sweden 23 .
Screening strategies
Five different screening strategies were simulated in the model, all with screening initiated at the age of 60 years in both men and women. Three strategies were taken from the SCREESCO study: no screening, screening twice with FIT, and screening once with colonoscopy. As a reference, two additional screening strategies with repeated screening up to the age of 80 years were also simulated: screening biennially with FIT and screening every 10 years with colonoscopy. These were based on the most commonly used programmes globally for screening with colonoscopy and FIT 9 .
Screening parameters
Data regarding participation rates in the first round of screening were projected based on early experience in the SCREESCO study ( Table 1 ). In the case of repeated screening, in the population of hypothetical individuals, it was assumed that 31 per cent could be categorized as 'never attendees' for FIT and 38 per cent for colonoscopy; and 40 per cent as 'always attendees' for FIT and 31 per cent for colonoscopy. These numbers were calculated based on early experience in the SCREESCO study and a study of repeated screening in the UK 37 . This means that these two subpopulations will never and always respectively attend for screening, irrespective of the number of times they are invited. The attendance rate at consecutive invitations to screening was assumed to be the same as at the first invitation 37, 38 . The specificity and sensitivity of colonoscopy were retrieved from a meta-analysis reported by Telford and colleagues 26 , and the corresponding values for FIT (cut-off value 10 μg) were from de Wijkerslooth et al. 17 .
Utility weights
Utility weights were applied to the simulated individuals in the model to create quality-adjusted life-years (QALYs). These utility weights included values ranging from 1 (representing full health) to 0 (representing death). The age-dependent baseline utility weights, based on the general population of Sweden, were obtained from Burström and colleagues 39 . The utility was adjusted for disease severity in individuals with cancer 36 . In the base-case scenario, screening procedures were not expected to affect health-related quality of life. However, in the sensitivity analyses, published data on willingness-to-pay to avoid colonoscopy were used to incorporate the potential discomfort of the procedure into the model 40 .
Unit costs and resource use
Data regarding resource use, in the event of cancer, were obtained from the Swedish Colorectal Cancer registry 21 23 . All unit costs were adjusted to the year 2016 and converted to euros using the exchange rate on 1 June 2016 (€1 = 9⋅3 Swedish krona). Details of the cost data used in the model and other input data are shown in Table 1 ; a more detailed description with all data used in the model is provided in Table S1 (supporting information).
Sensitivity analyses
To test the robustness of the model, the importance of uncertain parameters and assumptions made in the model was tested by varying the parameter value; these are presented as two-way sensitivity analyses. The statistical uncertainty of the cost-effectiveness analysis was studied using Monte-Carlo simulations. The results of the simulation were analysed using cost-effectiveness planes and acceptability curves. The probability that the treatment is cost-effective was calculated using a conservative threshold of €10 000 per gained QALY.
Results
The model enabled lifelong simulations of 1000 60-year-old hypothetical individuals in each of the five different screening strategies. Depending on the strategies implemented, different participation and detection rates of colorectal-related conditions are expected. The incidence of colorectal cancer was reduced by 25⋅0 and 11⋅7 per cent using colonoscopy once and FIT twice respectively. The cumulative number of colorectal cancer-related deaths when 1000 hypothetical individuals are invited and simulated through the five different screening strategies is shown in Fig. 2 . Considering only the analyses using the screening programmes being evaluated in the SCREESCO study, single colonoscopy led to the fewest colorectal cancer deaths. However, repeat screening with colonoscopy after 10 years and biennial FIT resulted in the largest decrease in colorectal cancer-related deaths. Fig. 3 shows the cumulative net cost of the four strategies with screening compared with no screening. Screening as performed in the SCREESCO study was suggested to lead to a short-term cost increase but a long-term cost saving. With repeated screening, higher total cumulative costs would be expected, as shown by the spikes in the curves due to costs incurred by the screening procedures. Cost and effects (QALYs) per 1000 invited individuals for the five screening strategies are shown in Table 2 . Compared with no screening, all four programmes showed a reasonable cost per QALY, but screening once with colonoscopy yielded a gain of 49 QALYs at a lower cost, whereas colonoscopy every tenth year resulted in the largest gain in QALYs but with a total cost increase of €124 600. Screening with FIT twice and biennially also gave a low cost per QALY gained, but with smaller numbers of QALYs gained and higher costs than corresponding strategies with colonoscopy ( Table 2) . FIT twice  26  20  30  45  18  26  27  26  22  26  Colonoscopy once  49  34  61  87  34  48  50  48  40  57  FIT, every 2 years  51  40  60  96  34  50  52  58  42  61  Colonoscopy, every 10 years  56  40  68  101  38  54  57  59  45  66 All results are compared with no screening per 1000 individuals invited. FIT, faecal immunochemical test; QALY, quality-adjusted life-year.
Sensitivity analysis
The reliability of the results was tested by sensitivity analysis ( Table 3) . The result was, as in most screening programmes, sensitive to changes in the discount rate. This is because positive effects could be observed several years after the screening. Colonoscopy was more sensitive than FIT to changes in the starting age and disease progression. The cost-effectiveness results were not sensitive to changes in the participation rates. Probabilistic sensitivity analysis showed that screening once with colonoscopy had the highest probability of being cost-effective if a QALY is considered to be worth €10 000. The probability that each strategy was the most cost-effective was 46⋅2, 1⋅1, 29⋅0 and 13⋅1 per cent for colonoscopy once, FIT twice, colonoscopy every tenth year and FIT every second year respectively.
Discussion
This study showed that screening for colorectal cancer is highly cost-effective; this result is similar to that of several previously published studies 13 . However, screening programmes differ between countries in terms of timing of implementation and context, such as different population preferences. The development of the test and new knowledge about the organization of programmes will continuously change the conditions and require new assessments when new programmes are implemented. Unlike previously published cost-effectiveness analyses, the present study was based partly on screening data from early experience in a head-to-head study of colonoscopy and highsensitivity FIT. When these tests are compared, the often debated factor is the participation rate. Projected data from early experience in the SCREESCO study showed a lower adherence to both colonoscopy (38 per cent) and FIT (50 per cent) than expected. Even using lower participation rates than those estimated in the study design, analysis of the screening strategies investigated in the SCREESCO study suggested that clinical and economic gains achieved with a single colonoscopy were dominant compared with screening with FIT twice, resulting in a better clinical outcome at lower cost, based on a lifelong perspective in a Swedish context. This screening strategy yielded the lowest cost per QALY gained. However, if the healthcare payer is prepared to pay more than €26 900 per QALY, the model suggested that additional QALYs can be gained at a reasonable cost by having screening with colonoscopy every tenth year.
Cost-effectiveness is one of several aspects to consider when making decisions regarding implementation of a colorectal cancer screening programme. Even though the investigated programmes were not very sensitive to changes in participation rates, other factors such as patient acceptance of the test and availability of human resources have to be considered. Furthermore, colonoscopy is a rather complicated method of bowel examination, which requires access to colonoscopy facilities. However, these are not available in many countries. The shortage of endoscopists, and variability and quality of the examination are other aspects to consider and require further investigation.
Simulation models have certain limitations, often owing to a lack of accurate data on lifelong costs and effects for calculating cost-effectiveness. Randomized clinical studies with sufficient follow-up to capture all relevant cost and effects are rarely available when economic evaluations are needed. Waiting for long-term follow-up data from RCTs before making decisions on implementation could lead to an unacceptable time lag for technologies that are probably effective. When long-term real-world or study data are absent and policy decisions are required, well grounded models based on overall knowledge of the clinical area are useful tools for decision makers. It is also important to update or construct new simulation models when better data become available. Furthermore, to draw meaningful conclusions from the model, uncertain parameters, such as the starting age, polyp-cancer pathway and disease progression, need to be studied rigorously in sensitivity analyses. For instance, screening both with colonoscopy and FIT remained cost-effective despite relatively large changes in these parameters (Table 3) , which reduces the uncertainty of the model predictions.
A limitation of this analysis, as in most cost-effectiveness studies, is the difficulty in including all the effects of screening. For instance, a parameter that was not included in the present analysis was the small but real effect of false-positive results on quality of life. It is likely that patients with a false-positive result have increased levels of anxiety for a short time. Incorporating this parameter in the present model might have a slightly negative effect on the result of screening.
Another limitation was that only colonoscopy and FIT were compared with no screening because these were used in the SCREESCO study. A FIT test with high sensitivity was used in SCREESCO to determine whether increased sensitivity leads to improved detection and survival in patients with colorectal cancer; however, this is usually not the case in screening programmes. Using a less sensitive FIT test would probably result in detection of fewer colorectal cancers, but with lower costs, meaning that the cost-effectiveness may not be affected. Moreover, several other screening technologies are available that should be studied in further analyses. For instance, CT colonoscopy has been shown to be a cost-effective screening alternative 30 . Five screening scenarios were considered here, but in a real-world context there are more options in terms of when the screening is initiated, how often it is repeated, and the possibility of different combinations of screening methods in the same programmes. The present sensitivity analysis showed that the starting age of screening affects the cost-effectiveness ( Table 3) . Further studies should analyse at what age the screening should start and when the screening should be repeated to optimize the programme.
All strategies that included screening were cost-effective compared with no screening. Repeated and single screening with colonoscopy were more cost-effective than FIT when lifelong effects and costs were considered. A single screening colonoscopy yielded the lowest cost per QALY, whereas screening every tenth year gained additional QALYs at a reasonable cost. However, other factors, such as patient acceptance of the test and availability of human resources, must also be considered.
